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Objective: A complex relationship between neuropsychiatric symptoms, personality
traits and neurochemical changes in patients with Parkinson’s disease (PD) has been
highlighted in the past several decades. In particular, a specific Parkinson personality
with obsessive traits has been described. However, despite the great amount of
anecdotal evidence, this aspect, together with its neurobiological, psychological and
clinical correlates, are still not clearly defined. Therefore, we performed a case-control
study in order to investigate the presence and rate of obsessive personality traits in PD
patients within the theoretical framework of cognitive-constructivist model. Moreover,
the relationship between PD personality and clinical, psychological and quality of life
(QoL) aspects in PD were investigated.
Methods: Fifty-one non-demented patients with probable or possible PD (not
demented) were recruited at the inpatient-outpatient San Luca Hospital, IRCCS Istituto
Auxologico Italiano. Control group was composed by forty-eight age- and education-
matched healthy volunteers. Patients underwent a neurological investigation including
Unified PD Rating Scale (UPDRS), Modified Hoehn and Yahr and Schwab and England
staging scales. The following psychological questionnaires were administered to the
overall sample: Personal Meaning Questionnaire (PMQ), State-Trait Anxiety Inventory-
Form Y (STAI-Y), Beck Depression Inventory (BDI), Symptom Check List-90 (SCL-90),
Short-Form Health Survey-36 (SF-36).
Results: No significant differences in personality styles were observed in PD patients
and controls, with a prevalence of phobic personal meaning organization (PMO) in
both groups. However, PD patients showed more anxiety, depression and obsessive-
compulsive (OC) symptoms than controls at the psychological questionnaires, as well as
poorer QoL levels. The intensity of personality traits, and in particular for the obsessive
personality style, were negatively associated with QoL and positively with disease
severity. No significant relationships were observed between personality and other
clinical aspects, such as side of onset and disease duration.
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Conclusion: Parkinson’s disease patients did not show a different personality profile
according to the cognitive-constructivist model with respect to controls. However, in
this population, a general enhancement in the tendency to codify experience by means
of specific cognitive and emotional patterns was associated to disease progression and
to a poorer QoL.
Keywords: Parkinson’s disease, personality, obsessive, quality of life, Personal Meaning Questionnaire
INTRODUCTION
Parkinson’s disease (PD) is a chronic neurodegenerative disorder
involving both motor and non-motor manifestations. In addition
to cognitive impairment and sleep disorders, patients with
PD often present with neuropsychiatric symptoms such as
depression, anxiety, apathy and impulse control disorders (ICDs)
as common non-motor symptoms. A complex relationship
between neuropsychiatric symptoms and neurochemical changes
(e.g., frontostriatal circuits and related dopamine functions) in
PD has been highlighted in the past several decades (Porter,
2016). In particular, ICD and apathy respectively represent hyper-
and hypo-dopaminergic symptoms and they are both influenced
by the introduction of dopaminergic drugs (Sierra et al., 2015).
Together with such aspects, a higher incidence of obsessive-
compulsive (OC) symptoms has been recorded in PD, although
with heterogeneous results (Maia et al., 2003; Harbishettar et al.,
2005; Kummer et al., 2009; Sharp et al., 2015). The association
between OC disorder and PD seems to be supported by the
common involvement of frontostriatal circuits in these disorders
and further suggested by an improvement of OC symptoms
after subthalamic stimulation (Williams et al., 2016). Moreover, a
relationship between OC symptoms and lateralization of motor
symptoms in PD patients has been detected (Kummer and
Teixeira, 2009b).
A high prevalence of OC personality disorder has also been
observed in PD patients, both drug-naïve and under dopamine
replacement therapy (Nicoletti et al., 2013, 2015). Therefore, it
can be hypothesized that OC personality disorder can be an early
manifestation of PD, partially independent from treatment.
A “parkinsonian personality” has been described since early
reports in the past century by means of several case-report,
case series, twin studies and case-control studies (Porter, 2016;
Santangelo et al., 2017, 2018).
The presence of premorbid personality profile in PD patients
has not been consistently supported by empirical evidence,
while the study of personality in patients with established PD
has led to more robust findings (Poletti and Bonuccelli, 2012;
Santangelo et al., 2018). Most of the collected evidence arises from
personality inventories developed according to the Cloninger’s
psychobiological model, that proposed three temperamental
dimensions based on three independent neurobiological systems:
the Novelty Seeking (dopaminergic system); the Harm Avoidance
(serotoninergic system); the Reward Dependence (noradrenergic
system) (Cloninger et al., 1993). Within this frame of reference, it
has been reported that PD patients are characterized by reduced
“novelty seeking” and high “harm avoidance.” Personality in PD
has also been assessed with tools developed according to the
Big-Five Model (McCrae and Costa, 1997); results have shown
higher level of neuroticism and lower levels of Openness and
Extraversion as distinguishing characteristics of PD compared
to healthy subjects (Santangelo et al., 2018). Some relationships
have also been observed between PD patients’ personality and
smoking habits, showing smoking as a significant mediator in
the relationship between personality traits and PD (Sieurin et al.,
2016) and revealing an association between smoking and novelty
seeking (Menza, 2000).
Despite the use of heterogeneous assessment instruments
and the varying qualities of the studies investigating OC
symptoms and personality traits in PD, features of introversion,
introspectiveness, inflexibility, industriousness, cautiousness,
morality and an anancastic personality type have been
consistently detected in such population.
These aspects converge in the description of an “obsessive
organization” of personality proposed by Guidano within the
cognitive-constructivist model within the field of psychotherapy.
Guidano described four basic patterns of self-coherence,
elaborated from the observation of characteristic cognitive styles
and attachment patterns in some psychopathological conditions.
Four “personal meaning organization styles” (PMO) have been
described: depressive, phobic, eating disorder, and obsessive
prone (Guidano, 1981, 1987). After successive elaborations of this
theory, the organizations were finally described as “personality
styles” which can be observed also in non-clinical populations
(Arciero, 2002; Picardi et al., 2003; Arciero et al., 2004).
Guidano focused on individual differences in the construction
of a sense of self, and his model is typological rather than
dimensional. In particular, individuals with an Obsessive PMO
are characterized by a sense of self primarily based on conscious
control of behavior and thinking, both of which are expected
to match abstract principles; main represented themes are that
of responsibility, anticipatory control, equity, order, certainty
and coherence. The development by Picardi and colleagues
(Picardi and Mannino, 2001; Picardi et al., 2003, 2004) of the
Personal Meaning Questionnaire (PMQ), aimed at assessing
the construct of PMO, provided new methods of personality
investigation within the cognitive-constructivist paradigm. This
instruments has been preliminarily used for the evaluation of
personality characteristics of neurological populations (Poletti
et al., 2017). Due to the categorical approach entailed in the PMQ,
it seems useful to detect the presence of a specific and prevalent
personality style and could improve the characterization of a
parkinsonian personality. Moreover, in the validation study,
PMQ cognitive-emotional organizations were compared to a set
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of criterion measures based on Cloninger’s and Big Five Models,
showing a good external validity (Picardi et al., 2003, 2004).
In the last decades, there has been increasing recognition of
the importance to address quality of life (QoL) of PD patients,
aside to managing the motor manifestations of the disorder.
QoL in PD is influenced by psychological symptoms, which are
partially related to dispositional attitudes or personality traits
(Soh et al., 2011; van Uem et al., 2016; Kim et al., 2017; Pontone
et al., 2017). Therefore, in addition to provide useful insights
into the underlying neurochemical and biological changes along
PD progression, the study of personality could help health
professionals to improve the assessment process and address
treatment strategies improving functional and emotional well-
being in PD.
In the present case-control study, we aim to investigate
the following aspects: the presence of higher rates, and higher
prevalence, of obsessive personality traits in a sample of PD
patients compared to age- and education-matched healthy
controls; the possible association of obsessive personality traits
with PD clinical factors (side of onset of motor symptoms, disease
severity and duration, smoking habits); the relationship between
personality traits and psychological symptoms commonly
observed in PD such as depression, anxiety and OC symptoms;
finally, the impact of personality traits on patients’ QoL.
MATERIALS AND METHODS
Subjects
Fifty-one patients diagnosed with probable or possible PD
according to Gelb et al. (1999) criteria were recruited at
the inpatient-outpatient San Luca Hospital, IRCCS Istituto
Auxologico Italiano. All but one patients were outpatients
receiving ambulatory care from neurologists after hospital
discharge. The only patients tested during the hospital recovery
was evaluated soon after the admission. The mean age of
patients was 68.20 years (SD = 9.19; range 47–81 years); mean
education was 12.82 years (SD = 3.96; range 5–18 years).
Marital and employment status were as follows: about 90%
of patients was married, the remaining being divorced or
single. About 65% were retired and 31% were still working;
the remaining never worked. Forty-eight age- and education-
matched healthy participants were recruited as control group
among volunteers from local associations and researchers’ friends
and relatives. The mean age of controls was 66.10 years
(SD = 7.13; range 51–83 years); mean education was 13.00 years
(SD = 3.45; range 5–18 years). About 90% of participants
was married, with the remaining being widowed, divorced
or single. For employment status, about half of them was
retired, while 40% was actually working and the remaining
has never worked.
Data were collected between March and December 2018.
Inclusion criteria for patients were: absence of dementia
(according to clinical examination and Mini Mental State
Examination – MMSE > 24/30); adequate educational level
required for filling out the psychological questionnaires (≥5 years
of education); if any, a stable psychiatric disorder (anxiety or
depression) without relevant fluctuations at the moment of
evaluation, as documented by our consultant neurologists at the
last visit prior to the inclusion in the study.
Inclusion criteria for control participants were the absence of
a history of neurological or psychiatric disorders and minimum
educational level as for patients.
The study protocol was approved by the Ethics Committee
of IRCCS Istituto Auxologico Italiano and all eligible subjects
received verbal and written information about the study. All
participants signed an informed consent, according to the
Declaration of Helsinki.
Clinical Examination
In PD patients motor severity and disease stage were assessed
through the Unified PD Rating Scale (UPDRS; Fahn and Elton,
1987), the Modified Hoehn and Yahr (Goetz et al., 2004) and the
Schwab and England (Schwab and England, 1969) scales.
Unified PD Rating Scale consists of four subscales: Section
I (Mentation, behavior, and mood); Section II (Activities of
daily living); Section III (Motor examination); Section IV
(Complications of therapy). The total scores of the subscales are:
Section I. 16 points; Section II. 52; Section III. 108; and Section
IV. 23. The UPDRS total score ranges between 0 and 199 points.
The Modified Hoehn and Yahr describes seven stages of
disease progression, from stage one, the earliest stage (unilateral
involvement only), to stage five, the most severe (wheelchair
bound or bedridden unless aided).
The Schwab and England Activities of Daily Living Scale rates
patients’ level of disability from 0 to 100%: a score of 0% refers
to bedridden patient and impaired vegetative functions (such as
swallowing, bladder and bowel function); a score of 100% refers
to a completely independent patient, able to manage its daily
activities without slowness, difficulty, or impairment.
For each patient, the following aspects were also recorded:
side of motor symptoms onset; disease duration (months);
antiparkinsonian and psychotropic therapies; smoking habits
prior and after disease onset.
Psychological and Personality
Assessment
Each subject underwent a battery of assessments investigating
personality, psychological and QoL features: The PMQ, the
State-Trait Anxiety Inventory-Form Y (STAI-Y), the Beck
Depression Inventory (BDI), the Symptom Check List-90-R
(SCL-90-R) and the Short-Form Health Survey-36 (SF-36). In
the present study, we adopted the validated Italian version of
each questionnaire. The described psychological and personality
questionnaires have been adopted in a previous study aimed to
evaluate personality features in other neurological populations
(Poletti et al., 2017).
The PMQ consists of a self-report questionnaire (Picardi
and Mannino, 2001; Picardi, 2003; Picardi et al., 2003) aimed
to explore thoughts, feelings and behaviors as expected in the
different PMOs. It is composed of 68 items to be answered
according to the level of agreement/disagreement or to a 5-
points Likert scale. Four 17-items subscales are present, each
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referring to a specific PMO: “phobic” (PP); “depressive” (DP);
“psychogenic eating disorders” (EDP); “obsessive” (OP). PMQ
Italian validation study showed the following psychometric
properties: internal consistency – Cronbach’s alpha: 0.65–0.82;
test-retest reliability – intra-class correlation: 0.58–0.84.
The STAI-Y (Spielberger, 1983; Pedrabissi and Santinello,
1989) is aimed at detecting and evaluating anxiety symptoms,
concerning both state (STAI-Y1) and trait (STAI-Y2) anxiety
components. It includes 40 questions, to be answered according
to both intensity and frequency of symptoms, with scores
ranging from 20 to 80. Internal consistency coefficients for
the scale have ranged from 0.86 to 0.95; test-retest reliability
coefficients have ranged from 0.65 to 0.75 over a 2-month interval
(Spielberger, 1983).
The BDI (Beck et al., 1979; Centomo and Sanavio,
Unpublished) evaluates depressive symptomatology, concerning
somatic, emotional, cognitive and motivational components.
The BDI consists of 21 items, concerning both cognitive-
affective (BDI CA, items 0–13) and somatic-performance
(BDI SP, items 14–21) symptoms of depression. Total score
ranges from 0 to 63, with higher total scores indicating
more severe depressive symptoms. According to BDI
psychometric properties, the Italian validation showed a
good internal consistency (Cronbach’s alpha = 0.82) and
good test-retest reliability (0.74) (Centomo and Sanavio,
Unpublished).
The SCL-90 inventory (Derogatis, 1994; Sarno et al.,
2011) was employed in order to evaluate a broad range
of psychopathological symptoms. This scale contains 90
items, highlighting mental disease according to 9 symptoms
dimensions: somatization (SOM), OC, interpersonal sensitivity
(IS), depression (DEP), anxiety (ANX), hostility (HOS), phobic
anxiety (PHOB), paranoid ideation (PAR), and psychoticism
(PSY). Evaluation of psychometric properties of the Italian
version showed a good internal consistency for all subscales
(values between 0.70 and 0.96) (Prunas et al., 2012).
A further questionnaire, the SF-36 (Ware and Sherbourne,
1992; Apolone et al., 1997), was also administered in order
to detect health related QoL, consisting of a multidimensional
tool made of 36 questions. Items refer to eight different health
domains: physical functioning (PF), role limitations due to
physical health (RP), bodily pain (BP), general health (GH),
energy (EN), social functioning (SF), role limitations due to
emotional problems (RE), and mental health (MH). The SF-
36 has eight scaled scores; the scores are the weighted sums
of the questions in each section. Scores range from 0 – 100,
with lower scores indicating more severe disability. Moreover,
the eight scales can be aggregated into two summary measures:
the Physical Component Summary (PCS) for the physical
dimension and the Mental Component Summary (MCS) for
the mental dimension. The scoring algorithm for PCS and
MCS were derived from an SPSS syntax for the Italian version
of SF-36 developed by the Mario Negri Institute1. SF-36
psychometric assessment showed Cronbach’s alpha coefficients
ranging from 0.77 to 0.93 and high internal consistency reliability
1http://lsi.marionegri.it/qdv/downloads/SF36%20SPSS.SPS
among different subgroups with lower values in the GH
scale, the young age groups and the more educated samples
(Apolone and Mosconi, 1998).
A researcher neuropsychologist administered the cognitive
screening tool for patients (MMSE). Data were collected with the
supervision of the neuropsychologist who assisted the patients in
the compilation of the self-report questionnaires.
Statistical Analysis
Descriptive data are reported as means ± standard deviations
for continuous variable and as absolute numbers for categorical
variables. Normality of continuous variables was assessed
with the Shapiro–Wilk test; the homogeneity of variances
was assessed with Bartlett test. According to the test for
normality of data, a normal distribution of PMQ subscores
was observed, while psychological questionnaires subscores
were almost totally not normally distributed. Thus, a mixed-
design ANOVA model was used, with clinical condition
(PD vs. control) as between-subjects variable and PMQ
subscores as within-subjects variable with pairwise t test
as post hoc. A Mann-Whitney U test was employed for
comparing PD and control’s scores at the psychological
questionnaires. In addition to total scores at each PMQ
subscale (EDP, DP, PP, and OP), for each individual the
presence of a prevalent PMO was calculated using the subscale
where total value was at least 10% higher of the second
most important subscale. A chi square test was employed
in order to assess possible differences in prevalent PMO
distribution among groups.
Correlational analyses between variables was carried
out through a bivariate Pearson’s correlation analysis (r) if
the assumptions of normality and homoscedasticity were
verified; otherwise, a Spearman’s rank correlation analysis
(rs) was employed.
The resulting p-values were corrected through a Benjamini–
Hochberg procedure for false discovery rate. An α level of 0.05
was used for all hypothesis tests. All data analyses were performed
using SPSS Statistics 24.
RESULTS
Characteristics of Subjects
Descriptive statistics concerning demographical and
psychological characteristics of PD patients and controls
are summarized in Table 1.
All patients were taking antiparkinsonian medication at the
time of the evaluation. Of the 50 patients (for one patient this
information was not available), eight were taking L-Dopa (LD)
alone; eleven LD in combination with dopamine agonists (DAs);
eight LD with Monoamine Oxidase inhibitors (MAO-I); ten LD
with MAO-I and DA, three LD with MAO-I and Catechol-O-
methyl transferase Inhibitors (COMT-I), one MAO-I only, one
DA with MAO-I, two MAO-I in combination with LD and
COMT-I, four LD in combination with DA, MAO-I and COMT-
I, and two LD with other types of antiparkinsonian treatment.
Moreover, 22 out of 51 patients (45%) were taking psychotropic
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TABLE 1 | Demographic, cognitive and psychological characteristics of PD patients and controls.
PD patients (N = 51) Healthy controls (N = 48)
Mean (SD) Mean (SD) t/U p-value Cohen’s d
Age 68.20 (9.19) 66.10 (7.13) 1.26 0.21 0.25
Education 12.82 (3.96) 13.00 (3.45) −0.24 0.81 0.05
MMSE correct score 27.89 (1.66) 28.89 (1.31) −2.89 0.00 0.67
BDI total score 12.29 (9.16) 4.65 (3.86) 542.50 < 0.001 1.09
BDI-CA 5.51 (5.41) 2.07 (2.31) 666.50 0.001 0.83
BDI-SP 6.76 (4.91) 2.73 (2.12) 507.50 < 0.001 1.06
STAI-Y1 47.06 (9.77) 39.23 (5.97) 582.00 < 0.001 0.97
STAI-Y2 49.67 (9.90) 42.92 (8.20) 793.00 0.003 0.74
SCL-90 SOM 11.00 (8.20) 6.00 (5.97) 688.00 < 0.001 0.70
SCL-90 O-C 9.25 (7.08) 4.56 (4.54) 686.50 < 0.001 0.79
SCL-90 IS 3.88 (3.56) 2.70 (2.99) 969.50 0.071 0.36
SCL-90 DEP 10.39 (7.60) 5.17 (4.23) 650.00 < 0.001 0.85
SCL-90 ANX 6.71 (5.62) 3.15 (3.48) 672.00 < 0.001 0.76
SCL-90 HOS 2.53 (2.93) 1.46 (1.75) 1008.00 0.120 0.44
SCL-90 PHOB 3.06 (4.55) 0.73 (1.28) 767.50 0.001 0.70
SCL-90 PAR 2.23 (2.26) 2.29 (3.08) 1077.50 0.294 0.02
SCL-90 PSY 3.61 (3.96) 1.69 (2.29) 823.50 0.004 0.59
SF-36 PF 67.70 (26.17) 86.35 (13.71) 668.00 < 0.001 0.89
SF-36 RP 45.50 (37.35) 83.33 (27.93) 525.00 < 0.001 1.15
SF-36 BP 51.36 (23.33) 75.04 (22.75) 576.00 < 0.001 1.03
SF-36 GH 39.36 (16.82) 64.56 (19.09) 366.00 < 0.001 1.40
SF-36 EN 50.10 (16.64) 67.91 (16.43) 550.50 < 0.001 1.08
SF-36 SF 60.84 (20.49) 85.06 (16.42) 450.50 < 0.001 1.30
SF-36 RE 56.66 (40.60) 84.06 (32.23) 736.00 < 0.001 0.75
SF-36 MH 64.48 (20.53) 76.87 (15.17) 743.00 0.001 0.69
SF-36 PCS 49.15 (22.48) 76.49 (18.52) 408.00 < 0.001 1.33
SF-36 MCS 59.38 (22.57) 76.11 (19.46) 659.00 < 0.001 0.79
PMQ EDP 49.45 (8.80) 47.60 (9.72) 0.99 0.324 0.20
PMQ DP 42.25 (10.63) 39.94 (8.38) 1.19 0.233 0.24
PMQ PP 62.96 (9.65) 60.85 (8.08) 1.17 0.243 0.24
PMQ OP 59.23 (9.15) 58.69 (7.06) 0.33 0.741 0.07
Bold numbers indicate statistical significance with p < 0.05. t = student’s t value; U = Mann–Whitney U test value; MMSE = mini mental state examination; BDI = Beck
Depression Inventory; BDI-CA = cognitive-affective BDI; subscore; STAI-Y1 = State Anxiety Inventory-Form Y; STAI-Y2 = Trait Anxiety Inventory-Form Y; SF-36 = Short-
Form Health Survey-36; SF-36 PF = physical functioning; SF-36 RP = role limitations due to physical health; SF-36 BP = bodily pain; SF-36 GH = general health;
SF-36 EN = energy; SF-36 SF = social functioning; SF-36 RE = role limitations due to emotional problems; SF-36 MH = mental health; SCL-90 = Symptom Check
List-90; SCL-90 SOM = somatization; SCL-90 OC = obsessive-compulsive; SCL-90 IS = interpersonal sensitivity; SCL-90 DEP = depression; SCL-90 ANX = anxiety;
SCL-90 HOS = hostility; SCL-90 PHOB = phobic anxiety; SCL-90 PAR = paranoid ideation; SCL-90 PSY = psychoticism; PMQ = Personal Meaning Questionnaire; PMQ
EDP = eating disorder personal meaning organization; PMQ DP = depressive personal meaning organization; PMQ PP = phobic personal meaning organization; PMQ
OP = obsessive personal meaning organization.
drugs: nine were taking SSRI antidepressant; five were taking
anxiolytic; seven were taking antiepileptic; three were taking
antipsychotic (prescribed alone or in combination).
In PD patients, mean UPDRS total score was of 24.78
(SD = 18.84; range 4–96); mean disease duration was 7 years
(SD = 5.5 years, range 1–24 years).
Information about PD patients smoking habits was available
for 44 subjects: of these, 52% (N = 23) never smoked, 41%
(N = 18) quit smoking, and 7% (N = 3) was still smoking at the
time of the evaluation.
Patients presented with higher level of psychological
symptoms than controls for several investigated domains
(depression, anxiety, somatization, OC symptoms, psychoticism)
(Table 1 and Figure 1). Moreover, QoL was lower in the
patients compared to controls, with a significant reduction in all
dimensions of SF-36 and in the two subcomponents concerning
physical and mental QoL. These results and between groups
comparisons at the psychological questionnaires are reported
in Table 1.
Personality Traits and PMO Prevalence
The mixed ANOVA showed the presence of within groups
differences in PMQ subscales scores (p < 0.001), while no
between group differences were detected in the four PMOs mean
values (p = 0.246). The pairwise t-test showed the presence
of significant differences among each PMO subscale in both
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FIGURE 1 | Mean scores at SCL-90 subscales in the PD patients and controls (mean ± SD). SCL-90 = Symptom Check List-90; SOM = somatization;
OC = obsessive-compulsive; IS = interpersonal sensitivity; DEP = depression; ANX = anxiety; HOS = hostility; PHOB = phobic anxiety; PAR = paranoid ideation;
PSY = psychoticism.
patients and controls with comparable distribution of higher
mean values; in particular, the highest values were observed for
PP, followed by OP, EDP, and DP subscales (see Table 1 and
Figure 2). The differences among subscales were more significant
for PD patients (p = 0.000) than for controls (p ranging between
0.055 and 0.000).
Moreover, a total of 22 PD patients (43%) and 17 controls
(35%) were classified as having a prevalent PMO (Figure 3). For
PD patients, 77% (N = 17) showed a prevalent PP personality
organization, 18% (N = 4) an OP and 5% (N = 1) an EP PMO.
In controls, a majority of participants (71%, N = 12) showed a PP
PMO and 29% (N = 5) an OP one. The Chi square showed no
significant difference between patients and controls in prevalent
PMOs distributions (p = 0.663).
In the PD group, significant correlations were observed
between PMOs mean values and scores obtained at the
psychological questionnaires. In particular, all PMQ subscales
correlated with depression (BDI total score and cognitive-
affective subscale, SCL-90-DEP; p ranging between <0.001 and
0.049; rs values between 0.293 and 0.565), anxiety (STAI-Y2, SCL-
90-phob, SCL-90-ANX; p ranging between <0.001 and 0.035; rs
between 0.315 and 0.486), SOM (SCL-90-SOM, p between 0.004
and 0.012; rs values between 0.292 and 0.467), OC symptoms
(SCL-90-OC, p-values between <0.001 and 0.016; rs between
0.302 and 0.497), PAR (SCL-90-PAR, p between <0.001 and
0.021; rs values between 0.395 and 0.517) and PSY (SCL-90-PSY,
p between <0.001 and 0.010; rs between 0.454 and 0.539).
In controls, fewer correlations were observed between PMOs
mean values and psychological symptoms. In particular, only
DP subscale correlated with depression (BDI total score – DP,
rs = 0.454, p = 0.024; SCL-90-DEP – DP, rs = 0.391, p = 0.048);
EDP and DP PMOs with trait anxiety at STAI-Y2, with rs ranging
between 0.314 and 0.479 and p = 0.024. Finally, EDP correlated
with OC symptoms at SCL-90 (rs = 0.441, p = 0.024).
Clinical Correlates of Personality in PD
No correlation was observed between disease duration (months)
and PMQ (EDP r = 0.063, p = 0.708; PP r = 0.144, p = 0.387; OP
r = 0.141, p = 0.346; DP r =−0.059, p = 0.705).
No significant differences in PMQ subscales were found
between patients with right or left side onset of PD: PP (t = 0.259,
p = 0.797), EDP (t = 0.745, p = 0.460), OP (t =−0.084, p = 0.933),
and DP (t = 0.238, p = 0.813).
Correlational analysis between obsessive personality traits and
disease severity showed a positive association between OP mean
values and UPDRS total score (rs = 0.416, p = 0.007), as well as
UPDRS III-Motor Examination (rs = 0.497, p = 0.004) subscore.
DP and PP PMOs were associated with UPDRS total score
(rs = 0.373, p = 0.019; rs = 0.400, p = 0.016 respectively) and with
UPDRS III subscore (rs = 0.414, p = 0.010; r = 0.445, p = 0.010,
respectively). UPDRS II subscore was only associated to DP one
(rs = 0.351, p = 0.026).
A negative correlation was also observed between Schwab and
England clinical scale total score and PMQ mean values for OP
(rs = −0.383, p = 0.019) and DP (rs = −0.327, p = 0.032) PMOs.
Conversely, the Modified Hoehn and Yahr staging scale score did
not correlate with OP mean score (rs = 0.086, p = 0.546), nor with
the other PMQ subscales (p> 0.05).
Finally, we investigated the possible association of smoking
habits with a specific PMO. This analysis was limited to the
“former smoker” and “never smoker” categories, due to the
paucity of subjects included in the “current smoker” group
(N = 3). Comparison between the two groups showed the absence
of significant differences between “never smoker” and “former
Frontiers in Psychology | www.frontiersin.org 6 October 2019 | Volume 10 | Article 2265
fpsyg-10-02265 October 10, 2019 Time: 17:16 # 7
Carelli et al. Personality in Parkinson’s Disease
FIGURE 2 | Distribution of PMQ mean scores in PD patients and control subjects (mean ± SD). EDP = eating disorder-prone PMO; DP = depression-prone PMO;
PP = phobia-prone PMO; OP = obsessive-compulsive prone PMO.
FIGURE 3 | Prevalence of PMOs in PD patients and control subjects (%). EDP = eating disorder-prone PMO; DP = depression-prone PMO; PP = phobia-prone
PMO; OP = obsessive-compulsive prone PMO.
smoker” for all PMOs: PP (t = 0.612, p = 0.544), EDP (t =−0.002,
p = 0.999), OP (t = −0.270, p = 0.788) and DP (t = −0.520,
p = 0.606) mean values.
Relationships Between Personality Traits
and Quality of Life
In the PD group we analyzed the relationship between OP PMO
and QoL. We fund significant negative associations between
OP PMO scores and SF-36 dimensions of general health (SF-
36-GH, rs = −0.309, p = 0.051) and role limitations due
to emotional problems (SF-36-RE, rs = −0.500; p < 0.001).
Mild correlations were also observed between other PMOs and
QoL, in particular concerning general health (PP rs = −0.344,
p = 0.036), role limitations due to emotional problems (DP
rs = −0.337, p = 0.032), mental health (EDP rs = −0.339,
p = 0.045; DP rs = −0.366, p = 0.020) and PF (DP
rs = −0.334, p = 0.032) dimensions. Conversely, in the
control group no correlation was observed between QoL and
PMOs subscores. When considering SF-36 physical (PCS) and
mental (MCS) subcomponents, mild to moderate correlations
were observed in PD group between MCS and all PMOs
(rs between −0.365 and −0.450, p between 0.004 and 0.034)
with the highest associations detected for obsessive PMO.
In control participants, no correlation was observed between
PMOs and PCS values.
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DISCUSSION
The presence of a prevalent personality organization in PD
patients, with respect to healthy controls, has not been
confirmed in our study. Moreover, the hypotheses of higher
prevalence and rates of obsessive personality traits in PD
patients is not supported by our data. Conversely, both
patients and controls scored higher in the phobic PMO
subscale. The latter finding, in the cognitive-constructivist
model, suggests the presence of alexitimic traits typical of
phobic organization, consisting of a difficulty to identify
emotional experiences and to relate emotional states to
somatic perturbations. Such results are in accordance with
Guidano’s considerations (Guidano, 1987) about distribution
of PMO in the general population and with previous studies
employing PMQ in other neurological conditions (Poletti et al.,
2017; Possa et al., 2017). Moreover, these data are also in
accordance with previous studies, highlighting an association
between premorbid anxious personality and risk of developing
PD (Bower et al., 2010). Conversely, our findings do not
support anecdotal descriptions, and previous studies showing
differences between patients and control subjects by means of
assessment tools referring to the Big Five and Psychobiological
Models (Poletti and Bonuccelli, 2012; Santangelo et al.,
2017, 2018). However, the employed questionnaires (i.e.,
the NEO Personality Inventory, the Eysenck Personality
Inventory, the Tridimensional Personality Questionnaire) are
not designed to specifically evaluate personality styles, but
rather to measure personality factors that contribute to different
profiles. Differently, the PMQ describes four specific personality
organizations, as specific rules for organizing immediate
experience in order to maintain internal consistency and
manage perturbations arising from the environment. Therefore,
our results do not exclude the possible presence of specific
personality traits or temperamental aspects in PD patients,
premorbid or concurrent to disease onset; rather, they suggest
that such traits, if present, do not contribute to define a
specific personality style when measured with PMQ within
the Guidano’s model. The combination of PMQ with other
traditional personality inventories could help to better define this
aspect in future studies.
Despite the absence of prevalent obsessive personality traits,
our PD patients showed a significant higher rate of obsessive,
anxiety and depressive symptoms, with respect to controls. These
data are in accordance with current knowledge about PD patients
showing a significant rate of neuropsychiatric symptoms in this
population (Maia et al., 2003; Kummer and Teixeira, 2009a). In
our sample, these symptoms showed a positive correlation with
all PMOs in the patients’ group and, to a lesser extent, in controls;
these findings suggest that the stiffening of PMOs’ characteristics,
rather than the prevalence of a specific PMO, leads to a greater
risk of developing psychological symptoms in PD patients.
In regard to clinical correlates of PD personality, we detected
a significant correlation between PMQ subscores (in particular
OP, DP, and PP) and disease severity (UPDRS), as well as
global disability level (Schwab and England staging scale). These
findings could suggest a general strengthening of all cognitive
and emotional patterns as the disease progresses and disability
increases, without any differences between PMOs. Conversely,
no association was found between PMQ subscores and disease
onset, and between symptom lateralization and personality traits.
Most of current literature about PD has not found significant
associations between personality traits, as well as OC symptoms,
and clinical measures such as disease severity and duration (Maia
et al., 2003; Harbishettar et al., 2005; Kummer and Teixeira,
2009b; Santangelo et al., 2017). Instead, a certain association
between symptom lateralization and personality aspects have
been found (Maia et al., 2003; Piacentini et al., 2011; Santangelo
et al., 2017). Our contrasting results could be due to the different
frame of reference for the study of personality and to the different
assessment tools employed.
In the present study, we also aimed to investigate the
relationship between smoking habits and personality aspects.
Our findings did not show any difference between “never
smoker” and “former smoker” patients on PMQ subscores.
Considerations about “current smoker” patients have not been
possible due to the paucity of patients in this category, in
accordance with literature showing smoking as a protective
factor for PD. It is possible that more information about
smoking habits, such as number of cigarettes/day and years of
smoking, and the recruitment of a larger sample of “current
smoker” patients could provide more conclusive findings
about this topic.
In regard to QoL, a specific effect of PD patients’ obsessive
personality traits was observed in our study: the obsessive PMO
was significantly and negatively correlated to QoL, suggesting a
strong impact of such personality style in determining both poor
general health and role limitations due to emotional problems.
Therefore, in PD, the strengthening of specific personality traits
and cognitive-emotional experiences substantially reduce the
adjustment capacity and coping abilities necessary to adapt to
such a progressive disease. Therefore, it seems that PD does not
modify the prevalence of different PMOs, but it could change the
relationship between personality and QoL.
A number of limitations in our study should be addressed.
First, patients’ recruitment did not consider the inclusion
of recently diagnosed, drug-naïve patients; instead, all our
patients were taking antiparkinsonian therapy. Thus, the effect
of dopaminergic treatment on personality features could not
be controlled, as well as the possible role of psychotropic
drugs; such possible moderating aspects should be controlled
in further analysis and investigations of PD personality.
Then, in the patients’ selection process we excluded patients
with overt dementia, and this could limit the generalization
of our results to other PD populations with more severe
cognitive impairment. However, by doing so, we assured
that personality trait changes (and other psychological
aspects) were not due to or influenced by a dementing
process. The administration of self-report psychological
questionnaires such as PMQ requires a certain degree of
cognitive integrity and the absence of obvious anosognosia
and anosodiaphoria; therefore, this limitation concerning
sample selection could be overcome or compensated only by
using other kind of measures such as informant-report ones.
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Moreover, the absence of a nosographic diagnosis concerning
psychopatological and personality dimensions, not having
included other more traditional personality assessment tools and
the adoption of a cross-sectional study may limit the explanatory
power of our results from a clinical point of view. Finally, the
detection of higher phobic PMO across different neurological
conditions (Poletti et al., 2017; Possa et al., 2017) could possibly
underlie some methodological bias that should be addressed in
order to improve PMQ validity and sensitivity.
As a consequence, our results cannot be considered conclusive
in regard to the assessment of personality style in PD patients
within the frame of cognitive-constructivist PMOs. In spite of
these limitations, the findings reported in the present study
represent the first contribution toward the understanding of the
personality profiles in PD patients according to the Guidano’s
cognitive-constructivist model.
A timely evaluation of personality in PD could help
clinicians to identify those patients at higher risk of developing
psychological disorders (anxiety, depression, OC symptoms),
behavioral alterations and poorer QoL as a consequence of
disease impact and progression.
We suggest that adequately assessing these profiles in clinical
practice and neuro-rehabilitation settings may be relevant to plan
pharmacological and/or psychological treatment tailored on each
patient’s characteristics.
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